Chest
-
Infectious Disease Case Reports Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Neutropenia complicates the management of critically ill patients. In the absence of malignancy or chemotherapy, its etiology and manifestations can be difficult to identify and portend a poor prognosis. Presented is a case of Neutropenic Enterocolitis (NEC). ⋯ Although a rare complication of medications, neutropenia resulting in NEC is unfortunate and potentially deadly. The case demonstrates the importance of follow up laboratory evaluation by primary care physicians after initiating new pharmacologic therapy.Reference #1: Irvin JD, Viau JM. Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril. American Journal of Medicine 1986; 81:46-50.Reference #2: Nesher L and Rolston KV. Neutropenic Enterocolitis, a Growing Concern in the Era of Widespread Use of Aggressive Chemotherapy. Clinical Infectious Disease 2013; 56: 711-717.Reference #3: Shamberger RC, Weinstein HJ, Delorey MJ, Levey RH. The medical and surgical management of typhlitis in children with acute nonlymphocytic (myelogenous) leukemia. Cancer 1986; 57:603-609DISCLOSURE: The following authors have nothing to disclose: Douglas Eddy, Joseph Guileyardo, Adan MoraNo Product/Research Disclosure Information.
-
Clinical practice guidelines recommend enteral over parenteral nutrition in critical illness and do not recommend early initiation. Few data are available on parenteral nutrition use or timing of initiation in the ICU or how this use may have changed over time. ⋯ Use of parenteral nutrition in US ICUs declined from 2001 through 2008 in all patients and in all examined subgroups, with the majority of parenteral nutrition initiated within the first 7 days in ICU; enteral nutrition use coincidently increased over the same time period.
-
Pulmonary and Sleep MedicineSESSION TYPE: Slide PresentationPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Obstructive Sleep Apnea (OSA) affects at least 1-5% of middle aged individuals in various ethnic populations. The National Cholesterol Education program's Adult treatment panel III recognizes metabolic syndrome as multiple risk factor for Cardiovascular disease. The prevalence of Metabolic Syndrome is increasing with the epidemic of obesity. The presence of obesity to both Obstructive Sleep apnea and Metabolic Syndrome prompted several studies that aimed to establish relationship between OSA and Metabolic Syndrome. It is therefore the aim of this study to determine the association of Metabolic Syndrome and Obstructive Sleep Apnea among patients at the Philippine Heart Center. ⋯ The following authors have nothing to disclose: Cristito Alea, Aileen BanzonNo Product/Research Disclosure Information.
-
Randomized Controlled Trial Multicenter Study
A validated risk model to predict 90-day VTE events in post-surgical patients.
VTE is the proximate cause of 100,000 deaths in the United States each year. Perioperative VTE risk among surgical patients varies by 20-fold, which highlights the importance of risk stratification to identify high-risk patients, in whom chemoprophylaxis can decrease VTE risk, and low-risk patients, for whom the risk-benefit relationship of prophylaxis may be unfavorable. ⋯ A weighted risk index quantifies 90-day VTE risk among surgical patients and identifies an 18-fold variation in VTE risk among the overall surgical population.